Jan Skvarka, Ph.D., M.B.A.
Board Member
Zentalis Pharmaceuticals, Inc. (ZNTL)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jan Skvarka, Ph.D., M.B.A.
Jan Skvarka, Ph.D., M.B.A. is recorded as Board Member at Zentalis Pharmaceuticals, Inc. (ZNTL). Zentalis Pharmaceuticals, Inc. reported in an 8-K filed September 12, 2022 that Jan Skvarka, Ph.D., M.B.A. was appointed Class III director, effective September 9, 2022.
“On and effective September 9, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Jan Skvarka, Ph.D., M.B.A., as a Class III director.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2022-09-09–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Zentalis Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Julie Eastland CEO, Board Member
- Kimberly Blackwell, M.D. CEO
- David M. Johnson Chairman
- Scott Myers Chairman, Board Member
- Cam Gallagher CFO
- Vincent Vultaggio CFO, Chief Accounting Officer
- Iris Roth COO
- Iris Roth, Ph.D. COO
- James B. Bucher General Counsel
- David Johnson Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.